---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-108145"
form_type: "8-K"
ticker: "ELOX"
cik: "0001035354"
company_name: "Eloxx Pharmaceuticals, Inc."
filed_at: "2021-08-20T23:59:59+00:00"
generated_at: "2026-06-29T08:33:42.443190+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Eloxx Pharmaceuticals appoints Daniel Geffken as Principal Accounting Officer

## Summary
- Daniel Geffken, Interim CFO since April 1, 2021, added role of Principal Accounting Officer on August 17, 2021.
- Geffken provides services through Danforth Advisors, LLC.
- No departure or change in CFO role; Geffken remains Principal Financial Officer.

## SEC filing metadata
- accession: 0001104659-21-108145
- form_type: 8-K
- ticker: ELOX
- cik: 0001035354
- company_name: Eloxx Pharmaceuticals, Inc.
- filed_at: 2021-08-20T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1035354/000110465921108145/0001104659-21-108145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1035354/000110465921108145/tm2125622d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-108145
- JSON: https://secwatch.observer/filing/0001104659-21-108145.json
- Plain text: https://secwatch.observer/filing/0001104659-21-108145.txt

## Key facts
- Executive change
  Daniel Geffken was appointed as Principal Accounting Officer at Eloxx Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Principal Accounting Officer
  source text: On August 17, 2021, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed the Company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the Company’s Principal Accounting Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1035354/000110465921108145/0001104659-21-108145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.